Background Recently, the hallmarks of aging were updated to include dysbiosis, disabled
macroautophagy, and chronic inflammation. In particular, the low-grade chronic …

In patients with cystic fibrosis (CF) lung damage secondary to chronic infection is the main
cause of death. Treatment of lung disease to reduce the impact of infection, inflammation …

Rationale: Ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR)
potentiator recently approved for patients with CF age 6 and older with the G551D mutation …

Description: The Cystic Fibrosis (CF) Foundation developed clinical care guidelines for the
prevention of Pseudomonas aeruginosa infection, the treatment of initial P. aeruginosa …

Background Respiratory tract infections with Pseudomonas aeruginosa occur in most
people with cystic fibrosis (CF). Established chronic P aeruginosa infection is virtually …

Background. Ivacaftor improves outcomes in cystic fibrosis (CF) patients with the G551D
mutation; however, effects on respiratory microbiology are largely unknown. This study …

Biofilm infections are one of the modern medical world's greatest challenges. Probably, all
non‐obligate intracellular bacteria and fungi can establish biofilms. In addition, there are …

Antimicrobial resistance is a significant threat to the treatment of infectious disease. Multiple
mechanisms of resistance to different classes of antibiotics have been identified and well …

Pulmonary exacerbations have very important consequences in cystic fibrosis (CF), both in
terms of current morbidity as well as implications for long term morbidity and mortality. Even …

Rationale: New isolation of Pseudomonas aeruginosa (Pa) is generally treated with inhaled
antipseudomonal antibiotics such as tobramycin inhalation solution (TIS). A therapeutic …